Efficacy of tanezumab vs. placebo on pain, function, safety for patients with knee OA .
تم تحديد هذه الدراسة على أنها ذات تأثير كبير محتمل.
يُقدّر مقياس التأثير العالي الذي يعتمد على الذكاء الاصطناعي من OE التأثير المحتمل لورقة بحثية ما من خلال دمج الإشارات من كل من المجلة التي نُشرت فيها والمحتوى العلمي للمقالة نفسها.
تم تطوير نموذج OE High Impact باستخدام أحدث تقنيات معالجة اللغة الطبيعية، ويتنبأ نموذج OE High Impact بدقة أكبر بأداء الاقتباس المستقبلي للدراسة أكثر من معامل تأثير المجلة وحده.
وهذا يتيح التعرف المبكر على الأبحاث ذات المغزى السريري ويساعد القراء على التركيز على المقالات التي من المرجح أن تشكل الممارسة المستقبلية.
OrthoEvidence Journal (OE Journal) - ACE Report
OE Journal. 2016;4(24):20 PLoS One. 2016 Jun 13;11(6):e0157105.4 randomized controlled trials (n=1833 patients) were included in this meta-analysis for the purpose of comparing analgesic efficacy and safety of tanezumab when compared to placebo treatment. Outcomes of interest included changes in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain, WOMAC physical function, patient global assessment, the incidence of adverse events, and treatment discontinuation due to adverse effects. Results demonstrated that patients who were given tanezumab had significantly improved pain, function, and global assessment scores when compared to the placebo group. However, significant increases in therapy discontinuation due to adverse effects, development of abnormal peripheral sensation, and peripheral neuropathy were also observed.
Were the search methods used to find evidence (original research) on the primary question or questions stated?
Was the search for evidence reasonably comprehensive?
Were the criteria used for deciding which studies to include in the overview reported?
Was the bias in the selection of studies avoided?
Were the criteria used for assessing the validity of the included studies reported?
Was the validity of all of the studies referred to in the text assessed with use of appropriate criteria (either in selecting the studies for inclusion or in analyzing the studies that were cited)?
Were the methods used to combine the findings of the relevant studies (to reach a conclusion) reported?
Were the findings of the relevant studies combined appropriately relative to the primary question that the overview addresses?
Were the conclusions made by the author or authors supported by the data and or analysis reported in the overview?
How would you rate the scientific quality of this evidence?
نعم = 1
غير مؤكد = 0.5
غير ذي صلة = 0
لا = 0
يقيّم تقييم معايير الإبلاغ الشفافية التي يبلغ بها المؤلفون عن الخصائص المنهجية والتجريبية للتجربة في المنشور. ينقسم التقييم إلى خمس فئات معروضة أدناه.
4/4
Introduction
4/4
Accessing Data
3/4
Analysing Data
4/4
Results
2/4
Discussion
Detsky AS, Naylor CD, O'Rourke K, McGeer AJ, L'Abbé KA. J Clin Epidemiol. 1992;45:255-65
مؤشر الهشاشة هو أداة تساعد في تفسير النتائج المهمة، وتوفر مقياسًا لقوة النتيجة. ويمثل مؤشر الهشاشة عدد الأحداث المتتالية التي يجب إضافتها إلى نتيجة ثنائية التفرع لجعل النتيجة غير مهمة. يمثل الرقم الصغير نتيجة أضعف ويمثل الرقم الكبير نتيجة أقوى.
لماذا كانت هناك حاجة لهذه الدراسة الآن؟
First-line treatment for pain associated with osteoarthritis of the knee often includes paracetamol, non-steroidal anti-inflammatory drugs, and other select analgesic medication. Although the efficacy of these treatments has been established through research for the majority of patients with knee OA, there still remains the potential risk of hepatotoxicity, gastrointestinal distress, and cardiorenal side effects. Tanezumab, a newly developed monoclonal antibody, has shown a promising effect in selectively inhibiting nerve growth factor (NGF), a critical element in the experience of osteoarthritic pain. A recent study has shown promising therapeutic efficacy when compared to placebo, however, its use in patients with knee OA specifically has been sparse and inconclusive.
ما هو سؤال البحث الرئيسي؟
What is the efficacy and safety of the use of Tanezumab for pain associated with osteoarthritis of the knee in terms of improvement in pain, function, patient global assessment, and incidence of adverse events?
- When compared to placebo, tanezumab groups demonstrated a significantly greater reduction in WOMAC pain scores (4 studies, n=1833 patients; SMD= 0.51 [95% CI 0.34-0.69], p<0.00001, I^2= 48%). (GRADE level of evidence: moderate)
- Tanezumab groups demonstrated a significantly greater reduction in WOMAC physical function scores when compared to placebo (4 studies, n=1833 patients; SMD=0.56 [95% CI 0.38-0.74], p<0.00001, I^2=52%). (GRADE level of evidence: low)
- Tanezumab groups demonstrated significantly greater improvement in PGA scores when compared to placebo (2 studies; SMD= 0.34 [95% CI 0.22-0.47], p<0.00001, I^2=0%). (GRADE level of evidence: moderate)
- When compared to placebo, tanezumab demonstrated a significantly higher risk of therapy discontinuation due to adverse events (3 studies; RR=2.89 [95% CI 1.59-5.26], p=0.0005, I^2=0%). (GRADE level of evidence: very low)
- Differences in incidence of serious adverse events (defined by requiring significant hospital intervention or causing disability, congenital anomaly, or death) were not significant between tanezumab and placebo groups (4 studies; RR=1.06 [95% CI 0.59-1.92], p=0.84, I^2=0%). (GRADE level of evidence: low)
- Tanezumab groups demonstrated a significant increase in the incidence of abnormal peripheral sensations when compared placebo (4 studies; RR=3.14 [95% CI 2.12-4.66], p<0.00001, I^2=16%). (GRADE level of evidence: low)
- Tanezumab groups demonstrated a significant increase in the incidence of peripheral neuropathy when compared the placebo group (2 studies; RR=6.05 [95% CI 2.32-15.81], p=0.0002, I^2=0%). (GRADE level of evidence: low)
- Subgroup analysis revealed that primary outcomes measures were not significantly different between tanezumab and placebo groups when tested for administration frequency (twice or thrice daily) or phase of the trial (phase II vs. phase III).
ما الذي يجب أن أتذكره أكثر؟
For patients with osteoarthritis of the knee, treatment with tanezumab resulted in significant improvements in WOMAC pain, WOMAC function, and patient global assessment while maintaining comparable incidence of serious adverse events when compared to placebo therapy. However, tanezumab was associated with a significantly increased risk of therapy discontinuation due to adverse events, particularly due abnormal peripheral sensation and peripheral neuropathy.
كيف سيؤثر ذلك على رعاية مرضاي؟
The results of this meta-analysis suggest that tanezumab may be of clinical benefit for patients with knee osteoarthritis as evidenced by significant improvements in pain, function, and assessment when compared to placebo. Significantly higher risks of therapy discontinuation (due to adverse effects), development of abnormal peripheral sensation and neuropathy were also noted. Further investigation with controlled methodology is recommended for validation of significant benefits. Direct comparisons made between tanezumab therapy and other popular modes of analgesic relief is also recommended to additionally compare the clinical and safety outcomes.
تنويه
هذا المحتوى الموجود في هذه الصفحة هو لأغراض إعلامية فقط وليس الغرض منه أن يكون بديلاً عن المشورة الطبية المتخصصة أو التشخيص أو العلاج. إذا كنت بحاجة إلى علاج طبي، اطلب دائمًا مشورة طبيبك أو اذهب إلى أقرب قسم طوارئ إليك. الآراء والمعتقدات ووجهات النظر التي يعبر عنها الأفراد في المحتوى الموجود في هذه الصفحة لا تعكس آراء ومعتقدات ووجهات نظر أورثوإيفيدنس.
0 من 4 مقالات مجانية شهرية غير مقفلة
